Drugs / LY4214835
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07258836 | Dec 2025 → Jan 2027 expected | neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4214835 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07258836 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT07258836 ↗ |